Investing With Us
- Growth EIS - Investor
  Invest in the future of UK technology
  
  Growth EIS - Adviser
  Build a portfolio of shares in the future of UK technology
  
  Co-Investor Circle
  Invest directly into single companies.
  
  Family Offices
  Co-Investing With Oxford Capital
  
  Business Relief
  Receive tax relief from EIS investments
  More Information:
  Our Strategy, Our Portfolio, Investment Risks
Seeking Investment
- Pre-Seed Investors
  Get pre-seed investment through the EIS.
  
  Seed Investors
  Get seed investment through the EIS.
  
  Cyber Security Investors
  Investing in a safer digital future.
  
  Digtial Health Investors
  Investing in a healthier future.
  
  Fintech Investors
  Bringing new talent to financial services.
  
  Retail Tech Investors
  Investing in disruptive retail tech across the UK
  More Information:
  Our Strategy, Our Portfolio, Investment Risks
About Us
- About Us
  Learn more about us
  
  Our Investment Approach
  Find our more about our approach to investment.
  
  Our Portfolio
  Browse our portfolio
  
  Our Team
  Meet our team
  
  FAQs
  See our frequently asked questions
Resources
- Introduction to EIS
  Learn more
  
  EIS Loss Relief Guide
  Learn more
  
  EIS Income Tax Relief
  Learn more
  
  EIS vs VCTs
  Learn more
  
  Is EIS a good investment?
  Learn More
  
  Are EIS Tax Free?
  Learn More
  Browse all our resources and news here.

September 20, 2021

Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic

Positive news from portfolio company Oxford BioTherapeutics – it has announced today that it has achieved another milestone with Boehringer Ingelheim for the progress of a second oncology drug candidate.

Interested in Building a portfolio of shares in the future of UK technology?

Choose an option below to request an information pack:

I’m an investor

I’m an adviser

Growth EIS - Investor

Growth EIS - Adviser

Co-Investor Circle

Family Offices

Business Relief

Pre-Seed Investors

Seed Investors

Cyber Security Investors

Digtial Health Investors

Fintech Investors

Retail Tech Investors

About Us

Our Investment Approach

Our Portfolio

Our Team

FAQs

Introduction to EIS

EIS Loss Relief Guide

EIS Income Tax Relief

EIS vs VCTs

Is EIS a good investment?

Are EIS Tax Free?

Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic

Share Post:

Oxford Office

46 Woodstock Road
Oxford
OX2 6HT

+44 (0) 1865 860 760